2004
Estimating the relative risk of developing melanoma in INK4A carriers
Berwick M, Orlow I, Mahabir S, Myskowski P, Coit D, Brady M, Roy P, Song Y, Canchola R, Barz A, Halpern A, Bolognia J, Eng S, Elahi A, Begg C. Estimating the relative risk of developing melanoma in INK4A carriers. European Journal Of Cancer Prevention 2004, 13: 65-70. PMID: 15075790, DOI: 10.1097/00008469-200402000-00010.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCase-Control StudiesChromatography, LiquidCyclin-Dependent Kinase Inhibitor p16FemaleGerm-Line MutationHumansMaleMelanomaMiddle AgedNeoplasms, Multiple PrimaryNevusNucleic Acid DenaturationOdds RatioPilot ProjectsPolymerase Chain ReactionPrevalenceRisk FactorsSkin NeoplasmsSurveys and QuestionnairesConceptsRisk factorsRelative riskMemorial Sloan-Kettering Cancer CenterStudy designSingle primaryCancer risk factorsMultiple primary melanomasRisk of melanomaNumber of neviPigmented lesion clinicNovel study designRare germline mutationsDermatology clinicCancer CenterNew study designsPrimary melanomaLesion clinicHigh prevalencePrimary casesPatientsMultiple primariesMelanomaGermline mutationsPilot studyFair skin
2000
A pilot study using nurse education as an intervention to increase skin self-examination for melanoma.
Berwick M, Oliveria S, Luo S, Headley A, Bolognia J. A pilot study using nurse education as an intervention to increase skin self-examination for melanoma. Journal Of Cancer Education 2000, 15: 38-40. PMID: 10730802, DOI: 10.1080/08858190009528651.Peer-Reviewed Original Research
1996
Rectal suppositories of 8-methoxsalen produce fewer gastrointestinal side effects than the oral formulation
Bolognia J, Freije L, Amici L, Dellostritto J, Gasparro F. Rectal suppositories of 8-methoxsalen produce fewer gastrointestinal side effects than the oral formulation. Journal Of The American Academy Of Dermatology 1996, 35: 424-427. PMID: 8784281, DOI: 10.1016/s0190-9622(96)90609-x.Peer-Reviewed Original ResearchConceptsGastrointestinal side effectsAbdominal painRectal suppositoriesSide effectsOral formOral liquid formClinical severity scoreOpen pilot studyGroup of patientsEntire treatment periodRoute of administrationMean scoreGastrointestinal symptomsSignificant nauseaRectal formClinical efficacyPsoriasis vulgarisPlasma levelsSeverity scoreTreatment periodOral ingestionSuppository formOral formulationPatientsNausea